DYRK2 is overexpressed in several tumors, including triple-negative breast cancer and multiple myeloma, which are known to rely heavily on proteasome activity for progression, and perturbation of DYRK2 activity impedes cancer cell proliferation and inhibits tumor growth (Banerjee et al., 2018; Banerjee et al., 2019). The gene discussed is DYRK2; the disease is triple-negative breast carcinoma.